In successive studies exploring the therapeutic feasibility of p300 inhibitors, it was found that A485, a p300-specific inhibitor, significantly inhibited the growth of ER+ breast cancer cells, which may be related to the down-regulation of enhancer H3K27ac, which inhibits the expression of ER target gene [64]. Here, EP300 is linked to breast carcinoma.